Dermata Therapeutics Inc (DRMA)vsRegeneron Pharmaceuticals Inc (REGN)
DRMA
Dermata Therapeutics Inc
$1.34
0.00%
HEALTHCARE · Cap: $5.21M
REGN
Regeneron Pharmaceuticals Inc
$664.52
-0.51%
HEALTHCARE · Cap: $70.03B
Smart Verdict
WallStSmart Research — data-driven comparison
REGN leads profitability with a 29.6% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 64/100 (C+).
DRMA
Avoid26
out of 100
Grade: F
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DRMA.
Margin of Safety
+50.5%
Fair Value
$1342.48
Current Price
$664.52
$677.96 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : DRMA
The strongest argument for DRMA centers on Price/Book.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : DRMA
The primary concerns for DRMA are Revenue Growth, EPS Growth, Market Cap.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
DRMA profiles as a value stock while REGN is a growth play — different risk/reward profiles.
DRMA carries more volatility with a beta of 0.69 — expect wider price swings.
REGN is growing revenue faster at 19.0% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (64/100 vs 26/100), backed by strong 29.6% margins and 19.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Dermata Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Dermata Therapeutics Inc. is a clinical-stage biotechnology company dedicated to innovating treatments for dermatological conditions, with a primary focus on its lead candidate, DMT310. Employing a proprietary delivery system, DMT310 aims to enhance the effectiveness of acne therapies and address critical unmet needs in the dermatology sector. With a strategically developed pipeline and a commitment to pioneering solutions, Dermata is poised to significantly impact the skin health landscape and improve patient outcomes. As the company progresses through its clinical trials, it holds the potential to become a transformative force in the treatment of various skin disorders.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?